Press

Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds

Apr 13 • 4 min read

Delic Holdings Corp (CSE: DELC | OTCQB: DELCF | FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its subsidiary, Delic Labs, received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on a number of compounds outside of psychedelic mushrooms,…

Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research

Apr 12 • 10 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF) and Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), are pleased to announce that they have entered into a definitive arrangement agreement pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind in an all-share transaction, by way of…

Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules

Apr 11 • 2 min read

Cybin Inc. (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that the World Intellectual Property Organization published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules (patent application no.PCT/EP2021/077057), further strengthening its long-term intellectual property position of psychedelic-based programs. “The publication of this PCT…

Homecoming Closes $4 Million Seed Funding Round To Scale Psychedelic Therapy Companion Tools

Apr 8 • 4 min read

Homecoming, the creator of industry-leading patient engagement tools for psychedelic therapy, announced today that it has closed an over-subscribed $4 million seed funding round. The company will use the funding to scale its products and services, enabling clinics and retreats to effectively streamline their operations, improve patient care, and deliver better outcomes. Investors in the…

Nova Mentis to Produce Psilocybin Capsules for Phase 2A Clinical Study

Apr 7 • 2 min read

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has consummated a contract with the Toronto Institute of Pharmaceutical Technology (TIPT) to formulate and manufacture psilocybin microdose capsules for its upcoming…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421